Press Releases
  Date Title View
ROCKVILLE, Md., April 24, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2018 af...
Posted: Apr 24, 2018
ROCKVILLE, Md., March 15, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today the pricing of its private offering of $350 million aggregate principal amount ...
Posted: Mar 15, 2018
ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today that, subject to market and other conditions, it intends to offer $350 million ...
Posted: Mar 13, 2018
ROCKVILLE, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host inv...
Posted: Mar 6, 2018
Fourth quarter 2017 total revenue of $88.4 million, a 42% increase over 2016, and fourth quarter 2017 net product sales of $86.3 million, a 41% increase over 2016.Fourth quarter 2017 operating earnings of $34.3 million, a 110% increase over 2016.Full year 2017 total revenue of $302.2 million, a 41% increase over 2016. Full year 2017 net product sal...
Posted: Feb 27, 2018
ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the fourth quarter and full y...
Posted: Feb 12, 2018
ROCKVILLE, Md., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), It is with great sadness that Supernus announces that William Nuerge, a valued member of its Board of Directors, passed away on January 10, 2018. Mr. Nuerge had a long and distinguished career in the pharmaceutical industry, including serving as CEO of...
Posted: Jan 12, 2018
ROCKVILLE, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host inve...
Posted: Jan 2, 2018
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host inve...
Posted: Nov 8, 2017
Third quarter net product sales were $78.1 million, a 40% increase over 2016. Third quarter operating income was $22.3 million, a 13% increase over 2016.Initiated Phase III clinical trials for SPN-812.Initiated Oxtellar XR investigator-sponsored trial in bipolar disorder.Increased full year 2017 net product sales guidance range to $290 million to ...
Posted: Nov 6, 2017
1
...
NextLast
= add release to Briefcase